SAGE Therapeutics

2 Biotech Takeout Targets Perfect for Biogen
2 Biotech Takeout Targets Perfect for Biogen
Motley Fool
Biogen
M&A
SAGE Therapeutics
Neurocrine Biosciences
Flag link:
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
Xconomy
SAGE Therapeutics
postpartum depression
Zulresso
brexanolone
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
Yahoo/Benzinga
Roche
SAGE Therapeutics
Ligand Pharmaceuticals
brexanolone
Tecentriq
Jazz Pharmaceuticals
JZP-110
Sanofi
Lexicon Pharmaceuticals
Zynquista
PhaseBio
AstraZeneca
Amarin
Leap Therapeutics
Strongbridge
Flag link:
With upcoming PDUFA, Sage proposes $500M follow-on
With upcoming PDUFA, Sage proposes $500M follow-on
BioCentury
SAGE Therapeutics
postpartum depression
Flag link:
Here's Why Sage Therapeutics Gained 48.9% in January
Here's Why Sage Therapeutics Gained 48.9% in January
Motley Fool
SAGE Therapeutics
SAGE-217
postpartum depression
clinical trials
Flag link:
The winners and losers from JPM 2019
The winners and losers from JPM 2019
Biopharma Dive
JPMHC 2019
Loxo Oncology
SAGE Therapeutics
Amarin
FDA
M&A
Flag link:
The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference
The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference
Motley Fool
Loxo Oncology
SAGE Therapeutics
Insmed
Flag link:
JP Morgan Healthcare Conference Update: Sage, Mersana, Shutdown Woes and Babies
JP Morgan Healthcare Conference Update: Sage, Mersana, Shutdown Woes and Babies
BioSpace
JPMHC 2019
SAGE Therapeutics
SAGE-217
Mersana
Novavax
Denali Therapeutics
AstraZeneca
Amarin
FDA
government shutdown
Flag link:
Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma
Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma
BioSpace
JPMHC 2019
M&A
Eli Lilly
Loxo Oncology
SAGE Therapeutics
Sanofi
Regeneron
Bristol-Myers Squibb
Celgene
Novartis
Gilead Sciences
Flag link:
Sage shrugs off potential competition in postpartum depression, asserts plan to remain independent
Sage shrugs off potential competition in postpartum depression, asserts plan to remain independent
Endpoints
SAGE Therapeutics
postpartum depression
SAGE-217
Flag link:
Sage Therapeutics pill improves postpartum depression in pivotal clinical trial
Sage Therapeutics pill improves postpartum depression in pivotal clinical trial
Stat
SAGE Therapeutics
clinical trials
postpartum depression
SAGE-217
Flag link:
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
Flag link:
PDUFA Date for Postpartum Depression Drug Delayed Three months
PDUFA Date for Postpartum Depression Drug Delayed Three months
CP Wire
FDA
SAGE Therapeutics
postpartum depression
Zulresso
Flag link:
PDUFA Date for Postpartum Depression Drug Delayed Three months
Zulresso
postpartum depression
SAGE Therapeutics
Flag link:
Sage depression drug to cost between $20K and $35K, if approved
Sage depression drug to cost between $20K and $35K, if approved
Biopharma Dive
SAGE Therapeutics
Zulresso
postpartum depression
FDA
drug pricing
Flag link:
With FDA Panel’s Nod, First Postpartum Depression Drug Nears Approval
With FDA Panel’s Nod, First Postpartum Depression Drug Nears Approval
Xconomy
FDA
advisory panels
SAGE Therapeutics
postpartum depression
brexanolone
Flag link:
FDA reviewers: REMS could allay safety concerns for Sage's brexanolone
FDA reviewers: REMS could allay safety concerns for Sage's brexanolone
BioCentury
FDA
SAGE Therapeutics
postpartum depression
SAGE-547
brexanolone
REMS
Flag link:
Sage Therapeutics’ chief scientist on discovering drugs and taking risks
Sage Therapeutics’ chief scientist on discovering drugs and taking risks
Drug Delivery Business News
SAGE Therapeutics
drug discovery
drug development
Flag link:
On a roll, Sage grabs a $575M deal on limited Asian rights to SAGE-217 — a potential gamechanger in depression
On a roll, Sage grabs a $575M deal on limited Asian rights to SAGE-217 — a potential gamechanger in depression
Endpoints
SAGE Therapeutics
SAGE-217
Asia
Shionogi
depression
Flag link:
Sage to Expedite Development of SAGE-217 in Major Depressive Disorder and Postpartum Depression
Sage to Expedite Development of SAGE-217 in Major Depressive Disorder and Postpartum Depression
CP Wire
SAGE Therapeutics
FDA
breakthrough status
SAGE-217
major depressive disorder
postpartum depression
Flag link:

Pages